Figure 1 The patient was instructed to monitor his peak expiratory flow (PEF) twice a day. The first 2 days after the third adalimumab administration he had a stable PEF of approximately 450 l/min. On the third day he developed dyspnoea, wheezing and a reduction in his PEF to 290 l/min. His PEF went back to baseline after 2 weeks.

volume in 1 s (FEV₁) reduced to 1.7 litres (46.8% of predicted) and FEV₁/forced vital capacity (FVC) ratio 55.9%. Since his RA responded favourably on adalimumab and there was not enough evidence to ascribe his respiratory complaints to this drug, it was decided to rechallenge him with adalimumab. During the third administration of adalimumab he still used prednisolone 20 mg/day and inhaled budesonide/formoterol twice daily. On the third day following adalimumab administration he developed dyspnoea, wheezing and a reduction in his peak expiratory flow (PEF) from 450 to 290 l/min (fig 1). These symptoms were less severe than at admission, probably because of concomitant treatment with corticosteroids. The prednisolone was increased to 50 mg/day and his PEF went back to baseline after 2 weeks. He resumed treatment with infliximab. His RA remained controlled and he did not suffer from bronchospasm again.

Bennett *et al* reported a patient with presumed adalimumab-induced asthma.¹ They hypothesised that once the tumour necrosis factor (TNF) α blocking adalimumab was introduced the T helper cell (Th)1 response characteristic for RA was suppressed, allowing the Th2-activated pathway to express itself as asthma.¹ However, patients with asthma have upregulation of the TNF α axis so one would expect suppression of asthmatic inflammation.^{2,3} Since Bennett and colleagues assumed that the pathophysiological mechanism causing adalimumab was a direct effect of the TNF α blockade, they suggested a class effect and decided not to treat their patient with other TNF α blocking agents.¹ Our patient used etanercept, adalimumab and infliximab within a short time frame and only reacted to adalimumab. This case therefore refutes the hypothesis that the asthmatic response is caused by blockade of TNF α , as well as the existence of a class effect. Symptoms

started 3 days after drug administration which is not compatible with anaphylaxis. A delayed-type T-cell mediated hypersensitivity reaction would be more likely.

At present it is unclear how often adalimumab has induced asthma-like symptoms. Because the use of adalimumab is increasing, this adverse event may become more prevalent in the future. We are the first to report adalimumab-induced bronchospasm with a positive rechallenge on the agent itself and negative challenges on etanercept and infliximab. We believe it is justified to make a switch to a different TNF α blocker under strict medical observation.

R Janssen,¹ I Krivokuca,² A A Kruize,³ L Koenderman,² J-W J Lammers²

¹ Department of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands; ² Department of Pulmonology, University Medical Centre Utrecht, Utrecht, The Netherlands; ³ Department of Rheumatology, University Medical Centre Utrecht, Utrecht, The Netherlands

Correspondence to: Dr R Janssen, Department of Pulmonology, St Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands; r.janssen@antonius.net

Funding: None

Competing interests: None.

Thorax 2008;**63**:472–473. doi:10.1136/thx.2007.086512

REFERENCES

1. Bennett AN, Wong M, Zain A, *et al*. Adalimumab-induced asthma. *Rheumatology* 2005;**44**:1199–200.
2. Berry MA, Hargadon B, Shelley M, *et al*. Evidence of a role of tumor necrosis factor α in refractory asthma. *N Engl J Med* 2006;**354**:697–708.
3. Erin EM, Leaker BR, Nicholson GC, *et al*. The effects of a monoclonal antibody directed against tumor necrosis factor- α in asthma. *Am J Respir Crit Care Med* 2006;**174**:753–62.

Renal impairment in cystic fibrosis

We read with interest the paper by Bertenshaw *et al*¹ on the incidence of acute renal failure (ARF) in patients with cystic fibrosis (CF) and would like to supplement these results with our findings. With increasing survival and therefore consideration for lung transplantation, monitoring adult patients with CF for renal impairment is assuming increasing importance (creatinine clearance <50 mg/ml/min is a contraindication to lung transplantation).²

We examined the prevalence of renal impairment in our stable adult CF population³ in Birmingham using the Cockcroft-Gault formula⁴ for estimating glomerular filtration rate (GFR). Between 1 January 2004 and 9 February 2005, 207 of our 273 adult patients with CF had at least one serum creatinine measurement; eight were excluded from analysis owing to established renal failure, one had subnormal creatinine precluding analysis and in six cases the data were incomplete, leaving 192 patients for analysis. Using the Cockcroft-Gault formula and the United Kingdom National Kidney

Foundation definition of renal impairment (GFR <90 ml/min), 50 of the 192 patients analysed had renal impairment; 26 of these had a current infective exacerbation of which 12 were receiving intravenous antibiotics. Thus, excluding those in a current exacerbation and those with established renal failure, 24/192 (12.5%) of our patients with stable CF had renal impairment. This is probably a conservative estimate as we know from a study in Liverpool in a *Pseudomonas*-colonised CF population that 24-hour urine collection diagnoses more renal impairment than the Cockcroft-Gault formula.⁵ Only one of the 50 patients identified as having renal impairment by the Cockcroft-Gault formula had a raised serum creatinine level, which is often the only test that first draws our attention to the problem.

Our findings support the need for regular renal assessment in adult patients with CF using measures superior to raised serum creatinine levels alone (eg, at least using the Cockcroft-Gault GFR formula for all routine annual reviews) to enable early diagnosis while we await “firmer inferences to be drawn regarding the causation of ARF in CF and allow avoidable precipitating factors to be identified”.

R Mukherjee, J Whitehouse, D Honeybourne

West Midlands Adult Cystic Fibrosis Centre, Birmingham Heartlands Hospital, Birmingham, UK

Correspondence to: Dr R Mukherjee, West Midlands Adult Cystic Fibrosis Centre, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS, UK; rmukherjee@doctors.org.uk

Thorax 2008;**63**:473. doi:10.1136/thx.2007.087098

REFERENCES

1. Bertenshaw C, Watson AR, Lewis S, *et al*. Survey of acute renal failure in patients with cystic fibrosis in the UK. *Thorax* 2007;**62**:541–5.
2. American Society for Transplant Physicians (ASTP)/American Thoracic Society (ATS)/European Respiratory Society (ERS)/International Society for Heart and Lung Transplantation (ISHLT). International guidelines for the selection of lung transplant candidates. *Am J Respir Crit Care Med* 1998;**158**:335–9.
3. Rabbani R, Mukherjee R, Whitehouse J, *et al*. Prevalence of renal impairment in an adult cystic fibrosis (CF) centre. *Eur Respir J* 2005;**26**(Suppl 49):622s.
4. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976;**16**:31–41.
5. Al-Aloul M, Miller H, Alapati S, *et al*. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. *Pediatr Pulmonol* 2005;**39**:15–20.

Is bronchodilation required routinely before diagnostic sputum induction? Evidence from studies with tuberculosis

Sputum induction (SI) by inhalation of nebulised hypertonic saline is an efficient

and non-invasive way of obtaining samples to assess airway inflammation and diagnose pulmonary infections such as tuberculosis (TB).^{1,2} Data published on the safety of SI are largely derived from subjects with obstructive lung disease. Yet on this basis a Working Group of the European Respiratory Society (ERS) recommended that all patients undergoing SI should receive pre-procedure bronchodilation with monitoring throughout by either serial forced expiratory volume in 1 s or peak expiratory flow rate (PEFR) measurements.³ Subjects with other respiratory conditions may not be at the same risk of bronchoconstriction as the original reference group. If so, then the recommended steps could be removed from routine SI, leading to a simplified procedure with no compromise in patient safety. Here we report our findings from routine clinical practice.

We prospectively observed 100 consecutive and unselected adult subjects undergoing SI to investigate possible TB. SI was performed using 3% hypertonic saline delivered via an ultrasonic nebuliser (Sunrise Medical, Wollaston, UK). To ensure good infection control, bronchospasm was assessed with disposable Mini-Wright peak flow meters (Clement Clarke International, Harlow, UK). PEFR was measured at baseline and then at 5, 10, 15 and 20 min. The preselected criteria for discontinuing SI were: (1) a fall in PEFR of >15% at any time point, (2) patient choice, (3) if the patient were deemed by the clinician performing the test to be unable to continue. Bronchodilators and resuscitation equipment were available if required. Equipment costs for generic salbutamol metered dose inhaler devices and the PEFR meter were calculated from the *British National Formulary* (March 2007) and manufacturer's data.

Median age of the 100 subjects was 43 years (range 18–68) and 60 were male. Six were ex-smokers and 26 were current smokers. Median baseline PEFR was 450 l/min (range 220–710). No subject had to stop the procedure because of respiratory symptoms or a fall in PEFR of >15% from baseline. The median change in PEFR was –6.6% (range –14% to +29%) with 76 subjects having a fall in PEFR, eight no change and 16 an increase in PEFR at 20 min. None of the patients required a bronchodilator post-procedure or developed symptoms thereafter. Three of 100 patients stopped at 15 min: one with headache, one because of nausea and one as they had collected an adequate sample.

Our data argue against the current ERS guidelines. We found a low rate of bronchospasm or complications following SI in our patients being investigated for TB (including current and ex-smokers). This suggests that it is safe to omit routine bronchodilation and PEFR measurements during SI in these subjects. We estimate that removing these

steps produces a saving of approximately £10 in cost and 10 min in time per procedure (which usually takes 30 min without this step). We would be interested to know whether other centres have had a similar experience in their clinical practice.

A Dunleavy, R A M Breen, MRF Perrin, M C I Lipman

Departments of Thoracic and HIV Medicine, The Royal Free Hospital, London, UK

Correspondence to: Dr A Dunleavy, Departments of Thoracic and HIV Medicine, The Royal Free Hospital, Pond St, London NW3 2QG, UK; annedunleavy@doctors.net.uk

Funding: This study was supported by a grant from The Henry Smith Charity.

Competing interests: None.

Thorax 2008;**63**:473–474. doi:10.1136/thx.2007.091439

REFERENCES

- Brightling CE.** Clinical applications of induced sputum. *Chest* 2006;**129**:1344–8.
- Brown M, Varia H, Bassett P, et al.** Prospective study of sputum induction, gastric washing, and bronchoalveolar lavage for the diagnosis of pulmonary tuberculosis in patients who are unable to expectorate. *Clin Infect Dis* 2007;**44**:1415–20.
- Pizzichini E** (Leader of the Working Group). Pizzichini MMM, Leigh R, Djukanovic R, Sterk PJ (Members of the Working Group). Safety of sputum induction. *Eur Respir J* 2002;**20**(suppl):9S–18.

Margarine: a supplement may be decisive

A recent study in *Thorax* described margarine intake as a risk factor for allergic diseases (*Thorax* 2007;**62**:677–83). This association has now been replicated in about 10 studies, but without any convincing explanation.¹ Margarine is the only food factor to date that is associated with allergic diseases without provoking any direct allergic reaction.

Margarine was invented by the French chemist Hippolyte Mège-Mouriès at the demand of emperor Napoleon III in 1869 as a cheap replacement food for his troops. The initial recipe contained water, skimmed milk and suet. Its use spread rapidly as a butter substitute, with the first factory in Oss/Netherlands exporting approximately 40 000 tons of margarine to Great Britain in 1883. As a raw material, lard was used at that time as well as copra, palm or train oil. As sales in the mid of the last century suffered from a somewhat poor quality image, modifications have been introduced, for example, to raise the content of polyunsaturated fats by using sunflower oil.

Since 1952, vitamin D₃ has also been added to margarine in West Germany. According to a new monograph on the history of vitamin D supplementation in Germany,² the company Merck delivered a highly concentrated oily vitamin solution to the Margarine Union who supplemented about the half of the 230 000 tons annually produced at that time. Since then margarine

has been one of the few if not the only continuously fortified food in Germany with a major brand containing ~1 IU/g D₃.

Given more recent experimental and epidemiological findings on the immunological action of vitamin D and its metabolites,³ it is possible that this vitamin D supplement may be responsible for the observed effect. Changing from butter to margarine indeed leads to ~30% higher 25-OH-calciferol serum level⁴ which may be in the effective range of serum levels linked to allergic rhinitis in the NHANES study.⁵

Possibly a trial on the Crete island could answer the question of whether or not there is any causal relationship between a margarine ingredient and allergy. Vitamin D supplements could be banned from margarine for a limited time as on a sunny island there is no major fear of vitamin D deficiency in the population. Will the allergy risk remain?

M Wjst

Correspondence to: Dr M Wjst, GSF-Forschungszentrum für Umwelt und Gesundheit, Ingolstädter Landstrasse 1, Neuherberg/Munich, Germany; wjst@gsf.de

Competing interests: None.

REFERENCES

- Devereux G, Seaton A.** Diet as a risk factor for atopy and asthma. *J Allergy Clin Immunol* 2005;**115**:1109–17.
- Haas J.** *Vigantol. Adolf Windaus und die Geschichte des Vitamin D.* Stuttgart: Wissenschaftliche Verlagsgesellschaft, 2007:222–4.
- Wjst M.** The vitamin D slant on allergy. *Pediatr Allergy Immunol* 2006;**17**:477–83.
- Kozłowska-Wojciechowska M, Makarewicz-Wujec M, Nowicka G.** Increased serum levels of vitamin D and calcium in young men after replacement of butter with soft margarine in usual diet. *Pol Arch Med Wewn* 2002;**108**:953–8.
- Wjst M, Hypponen E.** Vitamin D serum levels and allergic rhinitis. *Allergy* 2007;**62**:1085–6.

Authors' reply

We read with great interest the letter by Wjst proposing an alternative hypothesis for margarine supplementation by vitamin D as the risk factor underlying its positive associations with asthma and allergies. In our recently published study (*Thorax* 2007;**62**:677–83), we found that margarine intake was a risk factor for asthma and rhinitis symptoms among children in Crete. We hypothesised that the high concentration of n-6 PUFAs in margarine could partially explain the observed associations through modulation of the synthesis of IgE and inflammatory mediators.¹

The evidence regarding the effects of vitamin D on the development of asthma and allergies is controversial. Vitamin D has been shown to inhibit Th1 immune responses but its effects on Th2 responses are more complex and not fully elucidated. Moreover, genetic studies have provided early, although not clear, evidence of the